Roche

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

News

UCB, Roche, and IQVIA take lead in UK life sciences investme...

Pharma giant UCB is to invest around £1 billion in the UK as part of a second life sciences sector deal with the UK government, with industry names such as Roche and IQVIA also committing t

News

Genentech buys NASH biotech Jecure

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.

News

'Generation Z' happy to be diagnosed by chatbots

A survey involving young people from ‘Generation Z’ has revealed they want to see the NHS introduce digital solutions to help manage their care, with nearly two thirds saying they would be

News

Italy free to reimburse off-label Avastin, rules EU court

Novartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their approved Lucentis product for the eye disease age-related macular degeneration

News

Gene therapy firm BioMarin stages haemophilia musical

BioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression helps patients, as it develops an experimental cure for th

AZ's cancer drug fails again, Roche's rival gets new use

UCB, Roche, and IQVIA take lead in UK life sciences investme...

Genentech buys NASH biotech Jecure

'Generation Z' happy to be diagnosed by chatbots

Italy free to reimburse off-label Avastin, rules EU court

Gene therapy firm BioMarin stages haemophilia musical

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks